Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22) 22
humans (21) 21
oncology (17) 17
sarcoma (11) 11
antineoplastic agents - therapeutic use (9) 9
chemotherapy (9) 9
open-label (8) 8
pharmacology & pharmacy (8) 8
immunotherapy (7) 7
melanoma (7) 7
melanoma - drug therapy (7) 7
metastasis (6) 6
research (6) 6
sarcoma - drug therapy (6) 6
vemurafenib (6) 6
animals (5) 5
antineoplastic agents - adverse effects (5) 5
antineoplastic agents - pharmacology (5) 5
care and treatment (5) 5
clinical trials (5) 5
female (5) 5
ipilimumab (5) 5
mutation (5) 5
phase-ii (5) 5
sarcoma - pathology (5) 5
treatment outcome (5) 5
adult (4) 4
braf (4) 4
cancer (4) 4
dabrafenib (4) 4
drug therapy (4) 4
european organization (4) 4
medicine & public health (4) 4
mek (4) 4
metastatic melanoma (4) 4
middle aged (4) 4
multicenter (4) 4
pazopanib (4) 4
pembrolizumab (4) 4
protein kinase inhibitors - therapeutic use (4) 4
safety (4) 4
skin neoplasms - drug therapy (4) 4
solid tumors (4) 4
tumors (4) 4
aged (3) 3
analysis (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
b-raf (3) 3
clinical trials as topic (3) 3
combination (3) 3
development and progression (3) 3
disease progression (3) 3
docetaxel (3) 3
double-blind (3) 3
expression (3) 3
gemcitabine (3) 3
health aspects (3) 3
immunology (3) 3
immunotherapy - methods (3) 3
indoles - therapeutic use (3) 3
leiomyosarcoma (3) 3
male (3) 3
mapk (3) 3
medicine (3) 3
molecular targeted therapy (3) 3
neoplasm metastasis (3) 3
neoplasms - drug therapy (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
nivolumab (3) 3
prognosis (3) 3
programmed cell death 1 receptor - antagonists & inhibitors (3) 3
proto-oncogene proteins b-raf - antagonists & inhibitors (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
research design (3) 3
sulfonamides - therapeutic use (3) 3
t-cells (3) 3
trametinib (3) 3
trial (3) 3
1st-line (2) 2
activated protein-kinase (2) 2
angiogenesis (2) 2
angiogenesis inhibitors (2) 2
angiogènesi (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - pharmacology (2) 2
antibody (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - pharmacology (2) 2
antitumor-activity (2) 2
bevacizumab (2) 2
biomedicine, general (2) 2
bone neoplasms - genetics (2) 2
bone neoplasms - pathology (2) 2
cancer research (2) 2
cancer therapies (2) 2
caveolin 1 - genetics (2) 2
caveolin 1 - metabolism (2) 2
caveolin-1 (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1
by Sáinz-Jaspeado, Miguel and Huertas-Martinez, Juan and Lagares-Tena, Laura and Martin Liberal, Juan and Mateo-Lozano, Silvia and de Alava, Enrique and de Torres, Carmen and Mora, Jaume and de Muro, Xavier Garcial and Tirado, Oscar M
PLoS ONE, ISSN 1932-6203, 08/2013, Volume 8, Issue 8, p. e71449
Angiogenesis is the result of the combined activity of the tumor microenvironment and signaling molecules. The angiogenic switch is represented as an imbalance... 
TARGET | EPHA2 RECEPTOR | ACTIVATION | INVASION | TYROSINE KINASE | EWS/FLI-1 | MULTIDISCIPLINARY SCIENCES | EPHRINS | TUMOR | EXPRESSION | FAMILY | Humans | Receptor, EphA2 - metabolism | Sarcoma, Ewing - pathology | Bone Neoplasms - pathology | Cell Movement - genetics | Bone Neoplasms - metabolism | Heterografts | Female | Transcription, Genetic | Tumor Burden - genetics | Bone Neoplasms - genetics | Proto-Oncogene Proteins c-akt - metabolism | Disease Models, Animal | Sarcoma, Ewing - metabolism | Signal Transduction | Endothelial Cells - metabolism | Fibroblast Growth Factor 2 - biosynthesis | Gene Silencing | Caveolin 1 - genetics | Mice, Knockout | Protein Transport | Caveolin 1 - metabolism | Animals | Fibroblast Growth Factor 2 - genetics | Receptor, EphA2 - genetics | Cell Line, Tumor | Protein Binding | Neovascularization, Pathologic - genetics | Mice | Neovascularization, Pathologic - metabolism | Sarcoma, Ewing - genetics | Tyrosine | Development and progression | Fibroblast growth factors | Sarcoma | Phosphotransferases | Endothelium | Caveolin-1 | Laboratories | AKT protein | Biology | Metastasis | Kinases | Inactivation | Ewing's sarcoma | Cell adhesion & migration | Proteins | Angiogenesis | Signal transduction | Rodents | Fibroblasts | Protein-tyrosine kinase receptors | Nutrients | Children | Localization | Growth factors | Protein-tyrosine kinase | EphA2 protein | Fibroblast growth factor 2 | Ephrins | Young adults | Deactivation | Caveolin | Gene expression | Endothelial cells | Signaling | Neural networks | Ligands | Adults | Solid tumors | Prostate cancer | Cell migration | Tumors | Sarcoma d'Ewing | Neovascularization | Angiogènesi | Endoteli
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Encorafenib plus binimetinib: an embarrassment of riches
by Martin-Liberal, Juan
The Lancet Oncology, ISSN 1470-2045, 10/2018, Volume 19, Issue 10, pp. 1263 - 1264
ONCOLOGY | Vemurafenib | Benzimidazoles | Sulfonamides | Humans | Melanoma | Carbamates | Embarrassment | Proto-Oncogene Proteins B-raf
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
by Martin-Liberal, Juan and Furness, Andrew JS and Joshi, Kroopa and Peggs, Karl S and Quezada, Sergio A and Larkin, James
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 6/2015, Volume 64, Issue 6, pp. 765 - 767
The anti programmed cell death-1 (PD-1) antibodies pembrolizumab and nivolumab have been recently licensed by the Food and Drug Administration for the... 
Pembrolizumab | Immunology | MK-3475 | Medicine & Public Health | Nivolumab | Melanoma | Oncology | Cancer Research | Diabetes | PD-1 | ONCOLOGY | IMMUNOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Antineoplastic Agents - adverse effects | Humans | Melanoma - drug therapy | Middle Aged | Diabetes Mellitus, Type 1 - chemically induced | Female | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Diabetes Mellitus, Type 1 - immunology | Biological products | Type 1 diabetes | Development and progression | Biochemistry | Glutamate | Insulin | Liberalism | Diabetes therapy | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”
by Spain, Lavinia and Larkin, James and Martin-Liberal, Juan
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 6/2016, Volume 65, Issue 6, pp. 769 - 770
Oncology | Cancer Research | Immunology | Medicine & Public Health
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors
by Chesney, Jason Alan and Lutzky, Jose and Thomas, Sajeve Samuel and Nieva, Jorge J and Munoz Couselo, Eva and Martin-Liberal, Juan and Rodriguez-Moreno, Juan Francisco and Cacovean, Alex and Li, Huiling and Fardis, Maria and Gettinger, Scott N
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. TPS2648 - TPS2648
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Vemurafenib for the treatment of BRAF mutant metastatic melanoma
by Martin-Liberal, Juan and Larkin, James
Future Oncology, ISSN 1479-6694, 02/2015, Volume 11, Issue 4, pp. 579 - 589
Vemurafenib was the first selective BRAF inhibitor licensed in cancer. It is indicated for the treatment of patients affected by advanced melanoma with BRAF... 
chemistry | MEK | pharmacodynamics | ipilimumab | pharmacokinetics | vemurafenib | melanoma | BRAF | MAPK | dabrafenib | BLADDER-CARCINOMA ONCOGENE | MULTICENTER | MUTATION-POSITIVE MELANOMA | KINASE | FOLLOW-UP | OPEN-LABEL | DACARBAZINE | ONCOLOGY | B-RAF | TRANSFORMING GENES | INHIBITORS
Journal Article
Details down arrow
7. Full Text Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
by Herbst, Roy S, Prof and Arkenau, Hendrik-Tobias, MD and Santana-Davila, Rafael, MD and Calvo, Emiliano, MD and Paz-Ares, Luis, Prof and Cassier, Philippe A, MD and Bendell, Johanna, MD and Penel, Nicolas, Prof and Krebs, Matthew G, MD and Martin-Liberal, Juan, MD and Isambert, Nicolas, MD and Soriano, Andres, MD and Wermke, Martin, MD and Cultrera, Jennifer, MD and Gao, Ling, PhD and Widau, Ryan C, PhD and Mi, Gu, PhD and Jin, Jin, PhD and Ferry, David, MD and Fuchs, Charles S, Prof and Petrylak, Daniel P, Prof and Chau, Ian, MD
Lancet Oncology, The, ISSN 1470-2045, 2019, Volume 20, Issue 8, pp. 1109 - 1123
SummaryBackgroundPre-clinical and clinical evidence suggests that simultaneous blockade of VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances... 
Hematology, Oncology, and Palliative Medicine | THERAPY | ONCOLOGY | SAFETY | DOUBLE-BLIND | ANTIBODY | NIVOLUMAB | DOCETAXEL | CHEMOTHERAPY | Care and treatment | Lung cancer, Non-small cell | Analysis | Esophageal cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
by Arkenau, Hendrik‐Tobias and Martin‐Liberal, Juan and Calvo, Emiliano and Penel, Nicolas and Krebs, Matthew G and Herbst, Roy S and Walgren, Richard A and Widau, Ryan C and Mi, Gu and Jin, Jin and Ferry, David and Chau, Ian
The Oncologist, ISSN 1083-7159, 12/2018, Volume 23, Issue 12, pp. 1407 - e136
Lessons Learned Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is... 
MULTICENTER | CISPLATIN | ONCOLOGY | SAFETY | BEVACIZUMAB | PD-1 BLOCKADE | VEGF | PATIENTS PTS | COMBINATION | EXPRESSION | GEMCITABINE | Clinical Trial Results
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"
by Spain, L and Larkin, J and Martin-Liberal, J
CANCER IMMUNOLOGY IMMUNOTHERAPY, ISSN 0340-7004, 06/2016, Volume 65, Issue 6, pp. 769 - 770
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00262-016-1845-2 
ONCOLOGY | IMMUNOLOGY | Antibodies, Monoclonal - therapeutic use | Insulins | Humans | Diabetes Mellitus - drug therapy | Insulin | Diabetes therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Trabectedin for advanced soft tissue sarcomas: Optimizing use
by Reid, Alison and Martin-Liberal, Juan and Benson, Charlotte
Therapeutics and Clinical Risk Management, ISSN 1176-6336, 12/2014, Volume 10, pp. 1003 - 1011
Patients with locally advanced or metastatic soft tissue sarcoma have a poor outlook with median survival in the order of 1 year. There is therefore an urgent... 
ET-743 | Trabectedin | Optimal administration | Myxoid lipoarcomas | Soft tissue sarcomas | soft tissue sarcomas | SAFETY | EUROPEAN ORGANIZATION | DOXORUBICIN | IFOSFAMIDE | RETROSPECTIVE POOLED ANALYSIS | CHEMOTHERAPY | TRIAL | optimal administration | RANDOMIZED PHASE-II | trabectedin | HEALTH CARE SCIENCES & SERVICES | myxoid lipoarcomas | 1ST-LINE | ECTEINASCIDIN-743 ET-743 | Sarcoma | Drug therapy | Clinical trials | RNA polymerase | Metastasis | Gene expression | Patients | Cancer therapies | Confidence intervals | Tissue | Chemotherapy | Response rates | Tomography | Drug dosages | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The expanding role of immunotherapy
by Martin-Liberal, Juan and Ochoa de Olza, María and Hierro, Cinta and Gros, Alena and Rodon, Jordi and Tabernero, Josep
Cancer Treatment Reviews, ISSN 0305-7372, 2017, Volume 54, pp. 74 - 86
Highlights • Immunotherapy has revolutionized cancer treatment in recent years. • Several checkpoint inhibitors are already approved in a number of tumours. •... 
Hematology, Oncology and Palliative Medicine | Virus | Checkpoint inhibitors | Cell therapy | Vaccines | Co-stimulatory agonists | Combination | COMBAT CANCER | ANTIBODY | ADOPTIVE CELL TRANSFER | METASTATIC MELANOMA | ACTIVE SPECIFIC IMMUNOTHERAPY | ONCOLOGY | PHASE-3 TRIAL | ANTITUMOR IMMUNITY | RESISTANT PROSTATE-CANCER | T-CELLS | IPILIMUMAB | Immunotherapy - methods | Immunotherapy, Adoptive - methods | Antibodies, Monoclonal - pharmacology | Dendritic Cells - immunology | Humans | Ipilimumab | CTLA-4 Antigen - metabolism | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Oncolytic Virotherapy - methods | B7-H1 Antigen - metabolism | Cancer Vaccines - therapeutic use | Neoplasms - therapy | B7-H1 Antigen - antagonists & inhibitors | Neoplasms - immunology | Antibodies, Monoclonal, Humanized - pharmacology | CTLA-4 Antigen - antagonists & inhibitors | Immunotherapy | Medicine, Experimental | Medical research | Usage | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma
by Martin-Liberal, Juan and Pérez, Ezequiel and García Del Muro, Xavier
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 01/2019, Volume 28, Issue 1, pp. 39 - 50
Introduction: Soft-tissue sarcomas (STS) are a heterogeneous group of diseases that are characterized by a historic lack of active treatment options. However,... 
targeted therapy | Sarcoma | soft tissue sarcoma | chemotherapy | immunotherapy | combination | SIROLIMUS PLUS GEMCITABINE | 1ST-LINE TREATMENT | MULTICENTER | OPEN-LABEL | SPANISH GROUP | HIGH-RISK | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | IMATINIB MESYLATE | T-CELLS | PREVIOUSLY TREATED PATIENTS | Immunotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drugs, Investigational - pharmacology | Humans | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Sarcoma - drug therapy | Sarcoma - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Drug Design | Drugs, Investigational - administration & dosage | Antineoplastic Agents - pharmacology | Clinical Trials, Phase II as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text New RAF kinase inhibitors in cancer therapy
by Martin-Liberal, Juan and Larkin, James
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 06/2014, Volume 15, Issue 9, pp. 1235 - 1245
Introduction: Alterations in some key components of the MAPK pathway, such as BRAF, have been found to be related to the development of several malignancies. A... 
trametinib | MEK | RAS | RAF | vemurafenib | melanoma | MAPK | dabrafenib | ERK | Vemurafenib | Melanoma | Dabrafenib | Trametinib | ACTIVATED PROTEIN-KINASE | DOSE-ESCALATION TRIAL | PHASE-II | IMPROVED SURVIVAL | OPEN-LABEL | METASTATIC MELANOMA | MEK INHIBITOR | PHARMACOLOGY & PHARMACY | PAPILLARY THYROID-CARCINOMA | B-RAF | BRAF-MUTANT MELANOMA | Skin Neoplasms - drug therapy | Humans | Melanoma - enzymology | Oximes - therapeutic use | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Imidazoles - pharmacology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | Skin Neoplasms - enzymology | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Oximes - pharmacology | Indoles - pharmacology | Indoles - therapeutic use | Antineoplastic Agents - pharmacology | Imidazoles - therapeutic use | Proto-Oncogene Proteins B-raf - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Safety of pembrolizumab for the treatment of melanoma
by Martin-Liberal, Juan and Kordbacheh, Tiana and Larkin, James
Expert Opinion on Drug Safety, ISSN 1474-0338, 06/2015, Volume 14, Issue 6, pp. 957 - 964
Introduction: The immune checkpoint inhibitor pembrolizumab is the first anti-programmed-death-1 (PD-1) drug licensed by the FDA. It has been approved for the... 
pembrolizumab | cytotoxic T-lymphocyte-associated protein 4 | nivolumab | immune checkpoint | immunotherapy | ipilimumab | programmed-death-1 | melanoma | Pembrolizumab | Immune checkpoint | Cytotoxic T-lymphocyte-associated protein 4 | Immunotherapy | Ipilimumab | Nivolumab | Melanoma | Programmed-death-1 | PROGRAMMED DEATH-1 | TUMOR | LIGANDS | AUTOIMMUNITY | PHARMACOLOGY & PHARMACY | B7-H1 | MONOCLONAL-ANTIBODIES | PD-1 | EXPRESSION | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - drug therapy | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Animals | Antineoplastic Agents - adverse effects | Antibodies, Monoclonal, Humanized - pharmacology | Melanoma - drug therapy | Antineoplastic Agents - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Immuno-Oncology: The Third Paradigm in Early Drug Development
by Martin-Liberal, Juan and Martin-Liberal, Juan and Hierro, Cinta and Hierro, Cinta and Ochoa de Olza, Maria and Ochoa de Olza, Maria and Rodon, Jordi and Rodon, Jordi
Targeted Oncology, ISSN 1776-2596, 4/2017, Volume 12, Issue 2, pp. 125 - 138
Clinical researchers in oncology face the difficulty of developing new drugs for treating cancer patients. This challenge nowadays extends towards new horizons... 
Biomedicine, general | Medicine & Public Health | Oncology | LUNG-CANCER | SOLID TUMORS | ONCOLOGY | CANCER REGRESSION | CLINICAL-TRIAL DESIGN | DOUBLE-BLIND | END-POINTS | OPEN-LABEL | RESPONSE ASSESSMENT CRITERIA | RENAL-CELL CARCINOMA | T-CELLS | Drug Discovery - methods | Immunotherapy - methods | Neoplasms - immunology | Research Design | Humans | Neoplasms - drug therapy | Drugs | Analysis | Immunotherapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Targeted therapies in sarcomas: Challenging the challenge
by Liberal, Juan Martin and Lagares-Tena, Laura and Sainz-Jaspeado, Miguel and Mateo-Lozano, Silvia and Garcia Del Muro, Xavier and Tirado, Oscar M
Sarcoma, ISSN 1357-714X, 2012, Volume 2012, pp. 626094 - 13
Sarcomas are a heterogeneous group of mesenchymal malignancies that very often lead to death. Nowadays, chemotherapy is the only available treatment for most... 
Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Prognostic score for patients with advanced melanoma treated with ipilimumab
by Diem, Stefan and Kasenda, Benjamin and Martin-Liberal, Juan and Lee, Alexander and Chauhan, Dharmisha and Gore, Martin and Larkin, James
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 18, pp. 2785 - 2791
Abstract Background Immunotherapies like the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab show durable clinical benefit in patients with advanced... 
Hematology, Oncology and Palliative Medicine | Metastatic Melanoma | Prognostic Score | Ipilimumab | Risk Factors | SURVIVAL | REGRESSION | DABRAFENIB | MULTICENTER | LYMPHOCYTE | DACARBAZINE | ONCOLOGY | CONTINUOUS PREDICTORS | EXPERIENCE | SELECTION | Melanoma - blood | Multivariate Analysis | Predictive Value of Tests | Up-Regulation | Skin Neoplasms - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Skin Neoplasms - blood | Patient Selection | Time Factors | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Adult | Female | Retrospective Studies | Skin Neoplasms - pathology | Risk Assessment | Skin Neoplasms - immunology | Decision Support Techniques | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Remission Induction | Disease Progression | Melanoma - secondary | Biomarkers, Tumor - blood | L-Lactate Dehydrogenase - blood | Melanoma - immunology | Melanoma - drug therapy | London | Aged | Neoplasm Staging | Melanoma - mortality | Care and treatment | Immunotherapy | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights